Multiple myeloma is a disease characterized by the accumulation of a clonal population of terminally differentiated B lymphocytes within the bone marrow. For the vase majority of patients, the disease is incurable and average survival from diagnosis is approximately three years. Attempts to improve upon therapy for multiple myeloma over the last twenty years have resulted in only modest improvements. Due to the lack of success in developing curative therapy for multiple myeloma using currently available treatments, this laboratory is initiating studies designed to provide a better understanding of multiple myeloma biology. We hope that a better understanding of pathogenesis of multiple myeloma will permit the development of novel curative therapies. Studies into the biology of multiple myeloma have thus far failed to identify the molecular basis of the disease. Recently, studies of surface markers in myeloma cells exhibit a consistent pattern of surfacemarker expression distinct from plasma cells. We hypothesize that these differences represent an altered pattern of gene expression resulting from molecular events crucial in multiple myeloma pathogenesis. To test this hypothesis, we propose to compare mRNA expression in myeloma cells and normal plasma cells using the differential technique.

Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Prasher, J M; Elenitoba-Johnson, K S; Kelley, L L (2001) Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia. Oncogene 20:2946-55
Mojica, M P; Perry, S S; Searles, A E et al. (2001) Phenotypic distinction and functional characterization of pro-B cells in adult mouse bone marrow. J Immunol 166:3042-51
Lok, C N; Ponka, P (2000) Identification of an erythroid active element in the transferrin receptor gene. J Biol Chem 275:24185-90
Hsieh, F F; Barnett, L A; Green, W F et al. (2000) Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. Blood 96:2746-54
Wiesmann, A; Kim, M; Georgelas, A et al. (2000) Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor beta. Exp Hematol 28:128-39
Spangrude, G J; Cooper, D D (2000) Paradigm shifts in stem-cell biology. Semin Hematol 37:10-Mar
Wiesmann, A; Phillips, R L; Mojica, M et al. (2000) Expression of CD27 on murine hematopoietic stem and progenitor cells. Immunity 12:193-9
Searles, A E; Pohlmann, S J; Pierce, L J et al. (2000) Rapid, B lymphoid-restricted engraftment mediated by a primitive bone marrow subpopulation. J Immunol 165:67-74
Wiesmann, A; Spangrude, G J (1999) Marrow engraftment of hematopoietic stem and progenitor cells is independent of Galphai-coupled chemokine receptors. Exp Hematol 27:946-55
Perry, S S; Kim, M; Spangrude, G J (1999) Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. Cell Transplant 8:339-44

Showing the most recent 10 out of 19 publications